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ABSTRACT
The practice of administering sublingual immunotherapy for respiratory allergy is gaining more and more diffu-
sion worldwide as a consequence of the robust demonstration of clinical efficacy and safety provided by recent
high-powered and well-designed studies, confirming for individual seasonal allergens the results of previous
metanalyses in adult and pediatric populations. Preliminary evidence derives from recent rigorous trials on per-
ennial allergens, like house dust mites, and specifically designed studies addressed the benefits on asthma.
Emerging research suggests that SLIT may have a future role in other allergic conditions such as atopic derma-
titis, food, latex and venom allergy. Efforts to develop a safer and more effective SLIT for inhalant allergens
have led to the development of allergoids, recombinant allergens and formulations with adjuvants and sub-
stances targeting antigens to dendritic cells that possess a crucial role in initiating immune responses. The high
degree of variation in the evaluation of clinical effects and immunological changes requires further studies to
identify the candidate patients to SLIT and biomarkers of short and long term efficacy. Appropriate manage-
ment strategies are urgently needed to overcome the barriers to SLIT compliance.
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INTRODUCTION
The traditional subcutaneous route of administration
for allergen immunotherapy (SCIT) repeatedly dem-
onstrated to be effective in respiratory allergy. None-
theless, with injections some risk of severe or even fa-
tal adverse events still remains, partly attributed to
technical or human errors.1,2 Since a large part of the
reactions appear unpredictable despite that all pre-
cautions are taken, alternative routes of administra-
tion were sequentially explored. The sublingual route
for administering allergen immunotherapy (SLIT)
was introduced for the first time in 1986.3 Despite in-
itial skepticism owing to the missing characterization
of the extracts used and the poor design of the early
studies, SLIT gradually revealed itself as a promising
convenient route.4 Numerous randomized controlled
trials confirmed its clinical efficacy and post-
marketing surveys supported the good safety profile
during the last 15 years. Owing to these clinical evi-
dences, SLIT is officially accepted in international
consensus documents as a viable alternative to SCIT
for both adults and children4-6 and it is currently pre-
scribed at least as frequently as SCIT, representing in
some European countries 80% or more of new immu-
notherapy prescriptions.
Current research on SLIT is focused on confirming
the efficacy for all the different relevant allergens
(grass, birch, ragweed, house dust mites, cat), on a
better definition of allergen extracts and the improve-
ment of their safety and the immunological proper-
ties, on the identification of best treatment regimens,
on the possibility of extending the clinical indications.
In this review we describe the most recent step for-
wards in these fields of the SLIT development (Fig.
1).
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Fig.　1　The main steps in SLIT scientifi c advance.
-Efficacy and preventive effects in 
 rhinitis and asthma: pilot studies and
 small-sized RCTs
-Safety from post-marketing surveys
-Allergen extracts standardization
-Allergen Pharmacokinetics
-SLIT Mechanism
-Metanalyses in adults and 
 children
-Confirmatory large trials for grass
 pollen and mite
-Efficacy on allergic asthma
-Dose-response effects
-Sustained clinical effect
-Long term effects
-Local immunological effects
-Recombinant and modified 
 allergens
Further reseach needed:
-Efficacy for other relevant
 allergens
-Optimal dosages
-Optimal schedules
-Adjuvated extracts
-Biomarkers 
-Other indications
-Primary prevention
-Treatment strategies
1986 2006 2013 
THE CLINICAL EFFICACY OF SLIT
To date, the principal indication to SLIT remains al-
lergic rhinoconjunctivitis and most of the clinical data
derive from trials conducted in patients with that dis-
ease mainly in European countries. In more than 60
positive studies, two-thirds of them in dust mites and
grass allergy, the degree of clinical effect ranged
from 10 to 45% over placebo with greater than 20% in
about two-thirds.6
Meta-analyses suggested the efficacy of SLIT in al-
lergic rhinitis and asthma, in adults and children,7-10
although some concerns were raised about the risk of
publication bias, high heterogeneity and shortcom-
ings of clinical trials.11,12 The benefit was clearly dem-
onstrated in successive phase II and phase III trials
with grass tablets, in which a dose-dependent gradi-
ent was apparent and the magnitude of effect, sus-
tained along the treatment, ranged from 25 to 50%
over placebo.6 Preliminary reports from a very recent
randomized, multicentre, double-blind, high-powered
study on the efficacy and safety of mites tablets
showed that symptoms of allergic rhinitis were re-
duced compared to placebo after one year of treat-
ment.13
Very few small randomized trials compared head-
to-head SLIT with SCIT and could not demonstrate a
difference between the two routes. Indirect compari-
sons by metanalysis did not provide conclusive re-
sults,14 although for grass pollen a more prominent
effect was in favor of SCIT.15
SLIT efficacy and safety have been well established
in several US clinical trials utilizing single allergen
tablets or glycerinated extracts of grass pollen, rag-
weed and dust mite.16 Although SLIT does not have
regulatory approval in the United States, but it is used
in clinical practice, recent systematic reviews describ-
ing the effectiveness and safety of SLIT (off-label use
of subcutaneous-aqueous allergens for sublingual de-
sensitization) compared with other therapies for the
treatment of allergic rhinoconjunctivitis and asthma,
concluded that the body of evidence provides a mod-
erate to high support, but high-quality studies are still
needed to define optimal dosages.17,18 No life-
threatening adverse events were described, although
limitations in the standardization of adverse events
reporting were noted. This issue has been recently
faced by the scientific community, since there is no
universally accepted system to grade and classify
SLIT adverse events. A World Allergy Organization
Taskforce proposed a clinically based grading of the
severity of local adverse events, that are rather com-
mon with SLIT, based on the Medical Dictionary for
Regulatory Activities nomenclature system in order
to improve and harmonize surveillance and reporting
of the safety of SLIT.19
Some SLIT studies also evaluated the effects in
asthma, although rarely asthma was the primary out-
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come.6 As a consequence none of them has been ade-
quately powered or specifically designed to avoid bi-
ases. Only recently a positive therapeutic effect on
asthma control was demonstrated by a reduction of
more than 80 μgday inhaled budesonide for the
SLIT group compared to placebo after 1 year of daily
treatment, in a trial investigating whether the treat-
ment of 602 asthmatic patients allergic to house dust
mites with sublingual tablet can reduce the need of
inhaled corticosteroids.20 An ongoing study will be
able to establish whether this treatment can reduce
the frequency and the time to first exacerbation after
inhaled steroids reduction.21 The potential steroid
sparing effect, that acquires particular relevance con-
sidering the double exposition (nasal and bronchial)
in patients with AR and asthma, has been suggested
also by another recent study investigated whether
SLIT with chemically modified allergen extract, pro-
vides any advantage in real-life conditions and in a
relatively long term period, in achieving the control of
seasonal mild persistent asthma related to birch pol-
len.22 The high treatment tolerability in these adult
patients non adequately responding to fixed low-dose
of inhaled budesonide, suggests the perspective that
vaccines with reduced allergenicity could overcome
the limitations due to safety issue in uncontrolled or
severe asthma.
EXTENDING THE CLINICAL INDICATIONS
OF SLIT
Due to the favorable safety profile and acceptance by
patients, the use of SLIT has also recently been pro-
posed in non-respiratory allergy, including atopic der-
matitis (AD) and food allergy as explorative areas of
application.23
A number of observational studies suggested that
specific allergen immunotherapy may be a promising
treatment for AD, particularly when a IgE-mediated
component of the disease is involved.24 Atopic ec-
zema is a multifactorial disease, including complex
genetic modifications, responsible for skin barrier im-
pairment, and combinations of environmental and en-
dogenous factors that can direct its course. However
there is agreement on the possible link between
some forms of AD and allergic sensitization, mainly
to house-dust mites and foods, although some con-
cerns derive from the selection of the most relevant
allergen for desensitization, because patients are fre-
quently polysensitized.25 In a double blind random-
ized controlled trials, SLIT with house dust mites ex-
tract was given to 5-16 years children with AD strati-
fied according to disease severity for 18 months in ad-
dition to rescue therapy.26 With respect to controls,
from the 9th month onwards, patients with mild-
moderate disease allocated to active group achieved a
significant improvement in the SCORing Atopic Der-
matitis [SCORAD] and use of medications. Very re-
cently SLIT mite drops, given to 58 Asiatic patients
randomly compared to controls receiving only phar-
macotherapy, appeared safe and effective in a 12
months follow-up and could induce a tolerogenic
IgG4 response to mite allergen correlated with the fa-
vorable clinical efficacy.27 More controlled studies in-
volving a sufficient and representative numbers of
subjects are required to define the value of SLIT in
AD. Phase II trials are currently ongoing28 and new
experimental approaches contemplate the use of
SLIT in AD to investigate the primary prevention of
allergic sensitization and respiratory allergy. This
“early intervention” aimed at arresting the process
before it becomes persistent, was the strategy of The
Global Prevention of Asthma in Children (GPAC)
Study, a double blind placebo controlled trial to test
the hypothesis that enhancing the levels of mucosal
exposure of children at high risk of inhalant allergy
prior to the onset of sensitization would reduce the
likelihood of subsequent sensitization andor devel-
opment of asthma.29 Unfortunately firm conclusions
could not be drawn by this small pilot study, likely be-
cause of the objective difficulties in making infants re-
tain the sublingual drops under the tongue for
enough time to maximize mucosal penetration of the
appropriate dose required for triggering immu-
nologic processes.
Conditions like IgE-mediated food allergy, for
which dietary avoidance represents the common ap-
proach, may be good candidate for immunotherapy.
More than 10 years ago, preliminary studies investi-
gating SCIT in peanut allergy, showed uncertain re-
sult for benefits and unacceptable high risk for sys-
temic reactions, prompting research to explore the
potential of different administration routes.30,31 Con-
cerning SLIT, encouraging results came in the last
decade from five randomized controlled trials. In
2005 Enrique and colleagues observed a significant
increase in the symptoms threshold to oral food chal-
lenge with hazelnut in 12 adult patients receiving
SLIT, with a rate of systemic reactions equal to 0.2%
of administered doses.32 Similar results were found in
peach-allergic patients, treated with a purified extract
standardized for Pru p 3 content (lipid transfer pro-
tein of peach), along with a reduction of the skin spe-
cific reactivity. Numerous adverse events occurred,
mainly mild and self-resolving, but 16 reactions were
systemic.33 In 2011 peanut-allergic children following
6 months of dose escalation and 6 months of mainte-
nance dosing were able to tolerate 2500 mg (20 times
more peanut protein than the placebo group) during
the oral challenge, showing reduced skin response to
prick test and an curious increase of salivary specific
IgA-levels.34,35 Dosing side effects were primarily oro-
pharyngeal and uncommonly required treatment.
The clinical outcomes in all these three studies were
accompanied by the increase of IgG4 levels, but in-
consistent variations in IgE levels, IL10 and other
markers of immune-regulation. The most recent mul-
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ticenter study for peanut SLIT involved forty subjects
and after 44 weeks of therapy 70% of SLIT treated pa-
tients developed partial desensitization, compared to
only 15% of the placebo group.36 Oral immunotherapy
seems to be the most promising approach based on
the results from recent abundant literature.37 A ran-
domized study found that SLIT was less efficacious
for cow milk allergy desensitization than oral immu-
notherapy, but was accompanied by fewer systemic
side effects.38 These findings were confirmed by a re-
cent retrospective study comparing peanut-allergic in-
dividuals treated with either oral immunotherapy or
SLIT.39 Finally in the last three years an interesting
approach consisted in the use of SLIT with inhalant
allergens to treat oral allergic syndrome induced by
cross-reacting foods.40-42 Several immunological
changes have been related to the effects of immuno-
therapy in food allergy, but whether immunotherapy
is able to induce only desensitization, where continu-
ous allergen exposure increases the threshold of
clinical reactivity to the food, or tolerance, that is the
ability to consume a food without allergic symptoms
after treatment is ceased, is still matter of research.
Latex allergy seems to be a promising field of appli-
cation for SLIT but owing to the partial discrepancy of
the results of the available studies, it has not yet been
accepted as an indication to SLIT, although standard-
ized extracts are commercially available and used.43
Finally the potential of SLIT for hymenoptera
venom allergy was investigated in a couple of proof of
concept studies. In the first experience, 21 subjects
with history of systemic reactions to wasp sting, were
safely treated with sublingual vespula extract. No sig-
nificant immunological changes were found during
the treatment, but when 4 patients were stung again,
just 1 experienced isolated throat constriction.44 To
date only one randomized placebo-controlled study
was carried out in this field.45 This pilot trial adminis-
tered honeybee venom to 15 subjects with history of
large local reactions only. At the sting challenge after
six months of treatment, a significant reduction of the
wheal size was observed in the active group only, and
in 57% of patients the reaction was more than halved.
No adverse event was reported, but some concerns
derived from the ambiguous immunological changes
in respect to what was normally observed with injec-
tions. These encouraging explorative findings sug-
gest that dose-finding studies and larger trials are
needed to investigate the feasibility of SLIT in pa-
tients with hymenoptera venom allergy.
SLIT AND THE NATURAL PROGRESSION
OF RESPIRATORY ALLERGY
Immunotherapy for respiratory allergy is considered
as an adjunct to the pharmacological plan for the im-
mediate purpose of reducing symptoms and the need
for rescue medications.46 On the other hand immuno-
therapy acts as a biological response modifier and in-
duces profound changes in the immune response to
allergens, able to affect the natural progression of the
disease in the long term. This ‘preventive effect’ has
been shown with SLIT in a number of open random-
ized controlled trials.47,48 Another important aspect
not shared with the standard pharmacological treat-
ments is the long-lasting effect after discontinuation,
that has been seen observed in several SLIT studies
in adults and children.49-53 According to the literature,
the beneficial effects are maintained for 2-6 years af-
ter discontinuation of SLIT, nonetheless, a formal
demonstration of this long-lasting effect would re-
quire prolonged double-blind controlled trials, which
are not feasible from a practical and ethical view-
points. At present the results of randomized, double-
blind, placebo-controlled, multinational, phase III tri-
als, including 2 years of blinded follow-up after com-
pletion of a 3-year period of treatment, confirm the
disease modification by grass immunotherapy tablet,
but further studies are needed to address the poten-
tial long-term effects for other seasonal and perennial
allergens and to identify potential biomarkers of toler-
ance.54,55
All these ‘preventive’ effects gain particular interest
when considering the cost-effectiveness of the treat-
ment. A recent health technology assessment sug-
gests that SLIT when compared with pharmacother-
apy may become convenient from around 6 years, but
more robust estimates are needed to reach definitive
conclusions.56
IMPROVING THE SAFETY OF SLIT
The incidence of local side effects with SLIT (notably
mild itching and swelling of the lips and floor of the
mouth) has been estimated on average about 35%,
but typically it is observed up to 85% of patients in
clinical trials57; these events usually appears within
minutes or hours after intake and are of short dura-
tion (less than 14 days), frequently self-resolving or
requiring dose adjustment. Systemic reactions such
as urticaria, angioaedema and asthma, although sel-
dom, may occurs more frequently during dose escala-
tion. Albeit a dose-response relationship for safety is
not formally defined with SLIT, in part because of the
lack of a universal grading system, the occurrence of
side effects may be dose-dependent and allergen-
dependent.58,59 No fatal events has ever been de-
scribed but literature quotes twelve cases of anaphy-
laxis to SLIT, associated to multiple pollen allergen,
rash induction with latex extract, over-dosage and
high-dose SLIT in patients with previous reactions to
injective SIT.60,61
The efforts to improve the intrinsic safety of aller-
gen extracts represent an interesting approach for
the treatment optimization. Recombinant hypoaller-
genic allergens and allergoids have been precisely
developed with the aim of reducing the risks for
therapy-associated side effects. Recombinant DNA
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technology fully guarantees the characterization in
terms of physical, chemical, and immunologic proper-
ties in absence of non-allergenic proteins, polysaccha-
rides and contaminants in respect to extracts of natu-
ral source materials. This promising approach, lead-
ing in the future to the ‘patient’s tailored immunother-
apy’, can take the advantage of hypoallergenic vari-
ants specifically developed with the purpose of in-
creasing the administered doses and simultaneously
reducing the IgE-reactivity and the consequent risks
for therapy-associated side effect.62 Hypoallergenic
variants are well suited for subcutaneous application,
whereas it has been argued that wild-type recombi-
nant allergens are preferred for sublingual applica-
tion, due to the expected relevance of IgE-facilitated
allergen presentation by oral Langerhans cells in the
promotion of a regulatory T-cell response. Recombi-
nant allergen products for SLIT are in development,
and one of the first of these is based on tablet formu-
lations of rBet v 1,63 but due to regulatory and mar-
keting problems, the use of recombinant allergens
seems likely in the more distant future
The chemical modification of native allergens in or-
der to reduce their IgE-binding activity, as shown by
in vitro (immune-inhibition assays, basophil activa-
tion, and basophil mediator release) and in vivo tech-
niques (skin testing and nasal provocation), produces
hypoallergenic preparations that retain the T-cell re-
activity (antigenicity), and the ability to induce
allergen-specific IgG antibody response (immuno-
genicity), both essential for the clinical effects.64
However the chemical modification traditionally ob-
tained by reaction with glutaraldehyde or formalde-
hyde, produces polymeric allergoids, with high mo-
lecular weight, suitable for injective route only.65-67
The carbamylated allergoids, obtained with potas-
sium cianate by an extremely selective substitution of
the extract lysine residues, maintain structural con-
formation and low molecular size (monomeric aller-
goids) necessary for mucosal absorption. Prepara-
tions based on carbamylated allergoids currently rep-
resent the sole chemically modified allergens suited
for sublingual administration68,69 and numerous post-
marketing studies documented the optimal safety
profile, with incidence of side effects lower than 10%
of treated patients.70-72
IMPROVING THE IMMUNOLOGICAL PROP-
ERTIES OF SLIT
SLIT has been shown to work differently from SCIT,
being the extract captured by dendritic cells in the
oral mucosa (expressing high levels of FcεRI recep-
tors, MHC class I and II and costimulatory molecules
compared with their skin counterparts) and migrated
to draining lymph nodes, where regulatory or sup-
pressive T cells secreting IFN-γ andor IL-10 are
stimulated and blocking IgG1 and IgG4 antibodies
are generated. Some SLIT preparations have been de-
veloped with the aim of amplifying the effect by
modulating the immune response to the therapy.
One of these strategies contemplates the use of ad-
juvants (either bacterial or DNA-based), substances
with the potential of enhancing the immunogenicity
of antigens or allergens and largely investigated for
injective immunotherapy. Oral dendritic cells may be
the ideal target cells for adjuvanted SLIT vaccines,
enhancing the tolerance mediated by these cells
mimicking the natural contact of the individuals’ im-
mune system to allergens.73 Recently probiotics as
adjuvants for SLIT have been investigated in mice
models resulting in a enhanced tolerance induc-
tion.74,75 Another approach investigated the use of de-
toxified bacterial toxins or carbohydrate polymers ad-
juvanted to allergens as ‘microparticles’ and mucoad-
hesive particles, substances that could improve the
contact of allergenic extracts with the oral mu-
cosa.76-79 The research field dedicated to the develop-
ment of the molecular structure of SLIT extract to op-
timize the interactions with antigen presenting cells
seems particularly attractive and primising.80 Encour-
aging preliminary clinical findings in humans derive
from the first phase III, dose-ranging, placebo-
controlled trial with MPL-adjuvanted SLIT.81
Chemically modified allergen preparations suitable
for sublingual administration, obtained with carba-
mylation of the native allergen in order to maintain its
molecular dimension,82 have been developed and re-
vealed clinical efficacy and immunological effect in
several clinical trials.83,84 Carbamylated allergoids, in
addition to a reduced IgE-binding activity, showed en-
hanced bioavailability in pharmacokinetics studies as
a consequence of the partial resistance to enzymatic
degradation.85 This peculiarity is expected to en-
hance the amount of extract implicated in the toler-
ance induction, by coupling the stimulation of the oral
mucosa-associated and gut-associated immune sys-
tem with systemic absorption.
In the last decade some trials with dose-ranging de-
sign had demonstrated a dose-dependent clinical ef-
fect of SLIT with native extracts and identified the op-
timal maintenance dose for grasses in 15-25 μg major
allergen per day (approximately 50-times the monthly
dose of SCIT).86 The amplified features of SLIT
preparations using adjuvants and modified allergens
suggest that an adjusted dose tuning and dose re-
sponse effect evaluation is specifically required in re-
spect to SLIT traditional preparations.
ADDRESSING THE UNMET NEEDS
Recent advances in the field of SLIT addressed the
unmet needs remarked by the official positions of the
scientific community.6 The identification of the candi-
date patient, who would receive the most benefit from
SLIT, is still a challenge because no predictive
biomarker of efficacy has been identified so far, likely
because of the difficulties in establishing direct corre-
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lations between the variability of clinical endpoints
and the variety of immunological and inflammatory
changes observed during the treatment.87 If recent
research in SCIT strengthen the value of IgE-FAB in-
hibition and IgE-blocking factor as biomarkers of the
clinical response,88 for SLIT a molecular changes at
the level of dendritic cells, like the expression of
Complement component 1 (C1Q) and Stabilin-1
(STAB1), have been suggested as an early event in-
dicative of the subsequent orientation of adaptive im-
mune responses.89
Currently no conclusive data exist on which is the
best administration regimen (preseasonal, cosea-
sonal, pre-co-seasonal or continuous) of a SLIT
course, since direct head-to-head comparisons are
scarce. For pollen allergies a comparable efficacy re-
sults from preseasonal an precoaseasonal schemes
and these approaches seems to be the best choice
also from an economical viewpoint.90-92 Continuous
regimen appeared more effective than coseasonal
during the first year, but in the subsequent years
both seem equivalent.93 For what concern the optimal
duration of a SLIT course, a study suggests that a 4-
year duration is recommended because it induces a
long-lasting clinical improvement similar to that seen
with a 5-year course and greater than that of a 3-year
vaccination, but further research is needed to draw
conclusions.51
The standardization of allergen extracts is of pri-
mary relevance to the clinical efficacy of SLIT, but a
certain variability has been described in the biologi-
cal potency among different extracts of some aller-
gens.94 Manufacturers, in fact, have developed exten-
sive protocols for standardization and quality control,
but each company is using its own in-house reference
standards and units to express potencies. Although
some products reports the content of major allergen
in micrograms, comparisons between these informa-
tion should be considered with great caution in ab-
sence of accepted reference standards for the materi-
als and methods of quantitative analysis. A universal
standardization of the extracts would allow better
comparison of the various trials and products. The
CREATE project provides a model for the develop-
ment of a comprehensive panel of international refer-
ence preparations that will harmonize allergen meas-
urements worldwide.95
Despite that we entered the ‘molecular era’ of al-
lergy, combination vaccines, mimicking natural expo-
sure conditions, are still widely used. They offer a
broad coverage to the allergic patients by extending
the repertoire of allergens, however the potential risk
of de novo sensitization to epitopes present in the vac-
cine theoretically exists. Some cases of neosensitiza-
tion have been described with SCIT, nevertheless the
risk should be reduced when the allergen is deliv-
ered in an immune environment prone to tolerance
induction like the oral mucosa, as recently observed
for grass pollen and mite SLIT.96,97
Finally there is an need for identification of the po-
tential barriers to an optimal compliance to SLIT. A
recent retrospective analysis of a community phar-
macy database from The Netherlands, including 2796
patients who received SCIT and 3690 who received
SLIT, warned that the real-life persistence to the
treatment is better in SCIT than in SLIT users, but it
is low overall.96 An adequate action plan, including
education, frequent contacts, and strictly scheduled
visits recently obtained a significant reduction of
SLIT discontinuations,97 suggesting that the develop-
ment and implementation of measures that will en-
hance persistence and compliance to SLIT are ur-
gently needed.
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